MLYS

Mineralys Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website mineralystx.com
Employees(FY) 12
ISIN US6031701013

Performance

+3.91%

+20.82%

+66.95%

+27.78%

+29.65%

YTD

+30.5%

Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of MLYS 2025-05-23

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Technical Score of 64 supports this positive outlook. However, the Oscillators Score of 45 suggests a neutral stance, indicating potential caution in the short term despite the overall bullish trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MLYS

Stock Rank

Recent News & Updates

2025-05-24 04:30
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)(GlobeNewsWire)
2025-05-22 09:51
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going(Zacks Investment Research)
2025-05-20 08:00
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection(GlobeNewsWire)
2025-05-19 13:06
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy(Zacks Investment Research)
2025-04-23 05:23
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)(Globenewswire)
2025-03-29 02:30
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)(Globenewswire)
2025-03-24 23:28
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March(Insidermonkey)
2025-03-24 20:00
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET(Globenewswire)
2025-03-18 07:58
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?(Yahoo Finance)
2025-03-18 04:01
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock(Globenewswire)
2025-03-16 20:00
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo(Globenewswire)
2025-03-11 10:20
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock(Globenewswire)
2025-03-10 04:01
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock(Globenewswire)
2025-03-10 01:50
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate(Yahoo Finance)
2025-03-10 00:57
Mineralyss stock soars as hypertension pill scores in two pivotal trials(Yahoo Finance)
2025-03-09 19:00
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension(Globenewswire)
2025-03-09 18:30
Mineralys shares climb on study data for blood pressure drug(Yahoo Finance)
2025-03-07 03:01
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET(Globenewswire)
2025-02-13 02:19
Q4 2024 Mineralys Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
2025-02-13 02:10
Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ...(GuruFocus.com)
2025-02-12 07:00
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2025-02-11 18:00
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update(Globenewswire)
2025-02-05 16:05
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025(GlobeNewswire)
2025-02-05 03:05
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025(Globenewswire)
2025-02-04 11:20
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial(MT Newswires)
2025-02-04 08:00
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria(GlobeNewswire)
2025-02-03 19:00
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria(Globenewswire)
2025-01-08 19:29
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials(Yahoo Finance)
2025-01-08 08:00
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension(GlobeNewswire)
2025-01-07 19:00
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension(Globenewswire)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.

MLYS

Performance

Profile

Technical Analysis of MLYS 2025-05-23

Stock Analysis of MLYS

Recent News & Updates

Notifications

Upgrade to Pro

Pro Features Include: